Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Catalyst Pharmaceuticals (CPRX) over the last 12 years, with Q3 2025 value amounting to $4.8 million.

  • Catalyst Pharmaceuticals' Non Operating Income fell 2426.94% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year increase of 8237.04%. This contributed to the annual value of $21.1 million for FY2024, which is 17456.81% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Non Operating Income of $4.8 million as of Q3 2025, which was down 2426.94% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' Non Operating Income peaked at $11.3 million during Q4 2024, and registered a low of -$833000.0 during Q3 2023.
  • Moreover, its 5-year median value for Non Operating Income was $1.7 million (2023), whereas its average is $2.5 million.
  • Data for Catalyst Pharmaceuticals' Non Operating Income shows a peak YoY increase of 300845.07% (in 2022) and a maximum YoY decrease of 62258.06% (in 2022) over the last 5 years.
  • Over the past 5 years, Catalyst Pharmaceuticals' Non Operating Income (Quarter) stood at $71000.0 in 2021, then skyrocketed by 3008.45% to $2.2 million in 2022, then skyrocketed by 127.23% to $5.0 million in 2023, then soared by 126.08% to $11.3 million in 2024, then plummeted by 57.95% to $4.8 million in 2025.
  • Its Non Operating Income stands at $4.8 million for Q3 2025, versus $3.0 million for Q2 2025 and $7.9 million for Q1 2025.